. Author manuscript; available in PMC: 2023 Sep 18.

Published in final edited form as: J Clin Oncol. 2022 Oct 17;41(3):678–700. doi: 10.1200/JCO.22.01690

TABLE 7.

SBRT for Pretreated Patients With Oligometastatic Colorectal Cancer²¹

Outcome	Study Results	Quality of Evidence	Plain Language Summary
OS (1-year)	67.18% (95% CI, 42.1 to 92.2); 11 studies, I² = 0%	Low^a	OS was approximately 67% at 1 year for patients treated with SBRT
OS (2-year)	56.5% (95% CI, 36.7 to 76.2); 13 studies, I² = 0%	Low^a	OS was approximately 57% at 2 years with for patients treated with SBRT
LC (1-year)	67% (95% CI, 43.8 to 90.2); 13 studies, I² = 0%	Low^a	LC was approximately 67% at 1 year for patients treated with SBRT
LC (2-year)	59.3% (95% CI, 37.2 to 81.5); 13 studies, I² = 0%	Low^a	LC was approximately 59% at 1 year for patients treated with SBRT
Safety (toxicity)	Acute liver toxicity of up to 90%, usually mild-moderate Pooled grade 1–2 and grade 3–4 liver toxicity: 30.7% and 8.7%, respectively Other toxicities: Mild nausea and fatigue Liver failure: 0.6% Treatment-related deaths: 0.004%	Moderate	The toxicity profile was relatively manageable and limited for patients treated with SBRT

Abbreviations: LC, local control; OS, overall survival; SBRT, stereotactic body radiation therapy.

Downgrade: no comparison group. No clear dose-response gradient.